Pfizer may acquire companies, licenses to boost generic drugs business: report

According to a report in Handelsblatt, which cited the president of Pfizer's established products unit, David Simmons, the company is considering acquisitions and licensing deals to further bolster its presence in the generic drug market.

Simmons said Thursday that "we want to expand our product portfolio in this area," and he noted that the company's recent agreement with Aurobindo to licence generic products in the US and Europe will not be adequate for Pfizer to accomplish its strategic growth goals.

Simmons declined to comment on whether the company may attempt to buy Actavis or Ratiopharm.

To read more Top Story articles, click here.